Literature DB >> 27073203

Dual time-point imaging for post-dose binding potential estimation applied to a [11C]raclopride PET dose occupancy study.

Isadora Lopes Alves1, Antoon Tm Willemsen1, Rudi A Dierckx1, Ana Maria M da Silva2, Michel Koole1,3.   

Abstract

Receptor occupancy studies performed with PET often require time-consuming dynamic imaging for baseline and post-dose scans. Shorter protocol approximations based on standard uptake value ratios have been proposed. However, such methods depend on the time-point chosen for the quantification and often lead to overestimation and bias. The aim of this study was to develop a shorter protocol for the quantification of post-dose scans using a dual time-point approximation, which employs kinetic parameters from the baseline scan. Dual time-point was evaluated for a [11C]raclopride PET dose occupancy study with the D2 antagonist JNJ-37822681, obtaining estimates for binding potential and receptor occupancy. Results were compared to standard simplified reference tissue model and standard uptake value ratios-based estimates. Linear regression and Bland-Altman analysis demonstrated excellent correlation and agreement between dual time-point and the standard simplified reference tissue model approach. Moreover, the stability of dual time-point-based estimates is shown to be independent of the time-point chosen for quantification. Therefore, a dual time-point imaging protocol can be applied to post-dose [11C]raclopride PET scans, resulting in a significant reduction in total acquisition time while maintaining accuracy in the quantification of both the binding potential and the receptor occupancy.

Entities:  

Keywords:  Dual time-point; [11C]raclopride; binding potential; positron emission tomography; quantification

Mesh:

Substances:

Year:  2016        PMID: 27073203      PMCID: PMC5363466          DOI: 10.1177/0271678X16644463

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  24 in total

1.  D₂-receptor occupancy measurement of JNJ-37822681, a novel fast off-rate D₂-receptor antagonist, in healthy subjects using positron emission tomography: single dose versus steady state and dose selection.

Authors:  Mark E Schmidt; Peter de Boer; Randolph Andrews; Martine Neyens; Stefaan Rossenu; Demiana William Falteos; Erik Mannaert
Journal:  Psychopharmacology (Berl)       Date:  2012-07-07       Impact factor: 4.530

Review 2.  Consensus nomenclature for in vivo imaging of reversibly binding radioligands.

Authors:  Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2007-05-09       Impact factor: 6.200

Review 3.  Non-invasive imaging in experimental medicine for drug development.

Authors:  Paul M Matthews; Ilan Rabiner; Roger Gunn
Journal:  Curr Opin Pharmacol       Date:  2011-05-12       Impact factor: 5.547

4.  Test-retest reproducibility of dopamine D2/3 receptor binding in human brain measured by PET with [11C]MNPA and [11C]raclopride.

Authors:  Fumitoshi Kodaka; Hiroshi Ito; Yasuyuki Kimura; Saori Fujie; Harumasa Takano; Hironobu Fujiwara; Takeshi Sasaki; Kazuhiko Nakayama; Christer Halldin; Lars Farde; Tetsuya Suhara
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-12-14       Impact factor: 9.236

5.  A strategy for removing the bias in the graphical analysis method.

Authors:  J Logan; J S Fowler; N D Volkow; Y S Ding; G J Wang; D L Alexoff
Journal:  J Cereb Blood Flow Metab       Date:  2001-03       Impact factor: 6.200

6.  In vivo quantification of striatal dopamine D2 receptor occupancy by JNJ-37822681 using [11C]raclopride and positron emission tomography.

Authors:  Erik T te Beek; Peter de Boer; Matthijs Moerland; Mark E Schmidt; Nikie J Hoetjes; Albert D Windhorst; Bart N M van Berckel; Adam F Cohen; Joop M A van Gerven; Adriaan A Lammertsma
Journal:  J Psychopharmacol       Date:  2012-01-30       Impact factor: 4.153

7.  Test-retest reliability of central [11C]raclopride binding at high D2 receptor occupancy. A PET study in haloperidol-treated patients.

Authors:  S Nyberg; L Farde; C Halldin
Journal:  Psychiatry Res       Date:  1996-10-07       Impact factor: 3.222

8.  Within-subject comparison of striatal D2 receptor occupancy measurements using [123I]IBZM SPECT and [11C]Raclopride PET.

Authors:  Ana M Catafau; Marina Suarez; Santiago Bullich; Jordi Llop; Gianluca Nucci; Roger N Gunn; Claire Brittain; Marc Laruelle
Journal:  Neuroimage       Date:  2009-02-20       Impact factor: 6.556

Review 9.  Raclopride, a new selective ligand for the dopamine-D2 receptors.

Authors:  H Hall; C Köhler; L Gawell; L Farde; G Sedvall
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1988       Impact factor: 5.067

10.  Non-local means denoising of dynamic PET images.

Authors:  Joyita Dutta; Richard M Leahy; Quanzheng Li
Journal:  PLoS One       Date:  2013-12-05       Impact factor: 3.240

View more
  1 in total

1.  A dual-time-window protocol to reduce acquisition time of dynamic tau PET imaging using [18F]MK-6240.

Authors:  Ronald Boellaard; Michel Koole; Guilherme D Kolinger; David Vállez García; Talakad G Lohith; Eric D Hostetler; Cyrille Sur; Arie Struyk
Journal:  EJNMMI Res       Date:  2021-05-27       Impact factor: 3.138

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.